| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -98,963 | - |
| Depreciation | 900 | - |
| Stock-based compensation expense | 18,759 | - |
| Accretion of discount on investments, net | 2,060 | - |
| Prepaid expenses and other assets | 325 | - |
| Accounts payable and accrued other liabilities | -6,798 | - |
| Net cash used in operating activities | -88,487 | - |
| Acquisitions of property and equipment | 485 | - |
| Purchases of investments | 354,530 | - |
| Maturities of investments | 190,000 | - |
| Net cash used in investing activities | -165,015 | - |
| Proceeds from issuance of common stock and pre-funded warrants | 244,369 | - |
| Issuance costs associated with financings | 2,397 | - |
| Proceeds from issuance of common stock under espp | 757 | - |
| Proceeds from stock option exercises | 1,035 | - |
| Net cash provided by financing activities | 243,764 | - |
| Restricted cash and cash equivalents | - | 491 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -9,738 | - |
| Cash and cash equivalents, at carrying value, ending balance | - | 75,864 |
| Cash and cash equivalents at beginning of period | 59,897 | - |
| Cash and cash equivalents at end of period | 50,159 | 76,355 |
Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC)